Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.

Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
复制标题

DOI:
10.1002/pros.20962
复制
发表时间:
2009-07-01
期刊:
影响因子:
2.8
通讯作者:
Peng, Kah-Whye
Peng, Kah-Whye
中科院分区:
医学3区
文献类型:
--
作者:
Liu, Chunsheng;Hasegawa, Kosei;Russell, Stephen J.;Sadelain, Michel;Peng, Kah-Whye

文献摘要

参考文献

被引文献

相似文献

Live attenuated vaccine strain of measles virus (MV) has promising antitumor activity and is undergoing clinical testing in three different phase I cancer trials. The virus uses one of two receptors, CD46 which is ubiquitously expressed on all nucleated cells or CD150 which is expressed on immune cells, to infect cells. To minimize potential toxicity due to indiscriminate infection of normal cells, we have generated a fully retargeted MV that infects cells exclusively through the prostate-specific membrane antigen (PSMA) receptor, which is overexpressed on prostate cancer cells and tumor neovasculature. A single-chain antibody (scFv) specific for the extracellular domain of PSMA (J591) was inserted as a C-terminal extension on the MV attachment protein. Specificity of infection by the PSMA targeted virus was evaluated in parallel with the parental MV and a control virus which binds to CD38, a myeloma antigen. Antitumor activity of the PSMA retargeted virus was tested in both LNCaP and PC3-PSMA tumor xenograft models, with and without low dose external beam radiation. Replication of the PSMA targeted virus was comparable to the parental MV. The PSMA scFv efficiently redirected virus infection and cytopathic killing exclusively to PSMA positive prostate cancer cells and not PSMA negative cells. There was an additive effect on cell killing from radiation treatment and virotherapy. The PSMA virus induced tumor regression of LNCaP and PC3-PSMA tumor xenografts. Extensive areas of MV infection and apoptosis were seen in virus treated tumors. The PSMA retargeted virus warrants further investigation as a virotherapy agent.
DOI: 10.1016/j.virol.2004.08.036
发表时间: 2004-11-24
期刊: VIROLOGY
影响因子: 3.7
作者:
Hadac, EM;Peng, KW;Russell, SJ
通讯作者: Russell, SJ
DOI: 10.1182/blood-2008-05-155945
发表时间: 2008-12-15
期刊: BLOOD
影响因子: 20.3
作者:
Frecha, Cecilia;Costa, Caroline;Verhoeyen, Els
通讯作者: Verhoeyen, Els
DOI: 10.1002/jgm.1161
发表时间: 2008-04-01
影响因子: 3.5
作者:
Carlisle, Robert C.;Benjamin, Reuben;Fisher, Kerry D.
通讯作者: Fisher, Kerry D.
DOI: 10.1158/1078-0432.ccr-06-0759
发表时间: 2006-11-15
影响因子: 11.5
作者:
Hu, Jennifer C. C.;Coffin, Robert S.;Coombes, R. Charles
通讯作者: Coombes, R. Charles
DOI: 10.1111/j.1365-2559.2007.02635.x
发表时间: 2007-03-01
期刊: HISTOPATHOLOGY
影响因子: 6.4
作者:
Mhawech-Fauceglia, P.;Zhang, S.;Penetrante, R.
通讯作者: Penetrante, R.